GSK returned global rights for Wave Life Sciences’ RNA editing program WVE‑006 (AATD) to Wave, removing itself as development partner and restoring full control to Wave. Wave said it will pursue accelerated approval pathways and continue development independently. Company statements framed the split as a strategic decision by GSK and an opportunity for Wave to advance the program on its original timetable. The move underscores the practical and commercial uncertainties in nascent RNA editing technologies and shows how large‑pharma partnerships can be reversible when strategic fit shifts. Wave indicated regulatory plans and timelines for moving the program forward; investors will watch Wave’s capital runway and regulatory interactions as it assumes program responsibility.